Big Pharma is betting big on cancer drugs

Nancy Marshall-Genzer Jan 3, 2019
Share Now on:
HTML EMBED:
COPY
pxhere

Big Pharma is betting big on cancer drugs

Nancy Marshall-Genzer Jan 3, 2019
pxhere
Share Now on:
HTML EMBED:
COPY

Bristol-Myers Squibb announced Thursday that it’s going to acquire another drugmaker, Celgene. The deal is worth about $74 billion. The combined company will have nine products with sales of more than a billion dollars a year, including some blockbuster cancer drugs. The merger is a sign that Big Pharma is betting big on cancer medications.

Click the audio player above to hear the full story.

As a nonprofit news organization, our future depends on listeners like you who believe in the power of public service journalism.

Your investment in Marketplace helps us remain paywall-free and ensures everyone has access to trustworthy, unbiased news and information, regardless of their ability to pay.

Donate today — in any amount — to become a Marketplace Investor. Now more than ever, your commitment makes a difference.